Exploring the De Novo NMN Biosynthesis as an Alternative Pathway to Enhance NMN Production
ACS Synthetic Biology · 16.08.2024 · 13 (8) · 2425-2435
DOI: 10.1021/acssynbio.4c00115 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, online erschienen am 18.07.2024. Verfasst von Pengju Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China. Hauptthemen laut MEDLINE: Escherichia coli, Nicotinamide Mononucleotide, Metabolic Engineering, NAD. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences, Natural Science Foundation of Tianjin Municipality.
Abstract (Originalsprache)
Nicotinamide mononucleotide (NMN) serves as a precursor for NAD+ synthesis and has been shown to have positive effects on the human body. Previous research has predominantly focused on the nicotinamide phosphoribosyltransferase-mediated route (NadV-mediated route) for NMN biosynthesis. In this study, we have explored the de novo NMN biosynthesis route as an alternative pathway to enhance NMN production. Initially, we systematically engineered Escherichia coli to enhance its capacity for NMN synthesis and accumulation, resulting in a remarkable over 100-fold increase in NMN yield. Subsequently, we progressively enhanced the de novo NMN biosynthesis route to further augment NMN production. We screened and identified the crucial role of MazG in catalyzing the enzymatic cleavage of NAD+ to NMN. And the de novo NMN biosynthesis route was optimized and integrated with the NadV-mediated NMN biosynthetic pathways, leading to an intracellular concentration of 844.10 ± 17.40 μM NMN. Furthermore, the introduction of two transporters enhanced the uptake of NAM and the excretion of NMN, resulting in NMN production of 1293.73 ± 61.38 μM. Finally, by engineering an E. coli strain with optimized PRPP synthetase, we achieved the highest NMN production, reaching 3067.98 ± 27.25 μM after 24 h of fermentation at the shake flask level. In addition to constructing an efficient E. coli cell factory for NMN production, our findings provide new insights into understanding the NAD+ salvage pathway and its role in energy metabolism within E. coli.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
- School of Biological Engineering, Dalian Polytechnic University, Dalian 116034, China.
- College of Life Science, Tianjin Normal University, Tianjin 300382, China.
ORCID-Profile: Changhao Bi, Xueli Zhang
Förderung
- National Natural Science Foundation of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Natural Science Foundation of Tianjin Municipality
- National Key Research and Development Program of China
- Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project
Zitieren
APA
Wang, P., Ma, Y., Li, J., Su, J., Chi, J., Zhu, X., Zhu, X., Zhang, C., Bi, C., & Zhang, X. (2024). Exploring the De Novo NMN Biosynthesis as an Alternative Pathway to Enhance NMN Production. ACS Synthetic Biology, 13(8), 2425-2435. https://doi.org/10.1021/acssynbio.4c00115
Vancouver
Wang P, Ma Y, Li J, Su J, Chi J, Zhu X, et al. Exploring the De Novo NMN Biosynthesis as an Alternative Pathway to Enhance NMN Production. ACS Synthetic Biology. 2024;13(8):2425-2435. doi:10.1021/acssynbio.4c00115
BibTeX
@article{Wang2024,
author = {Wang, Pengju and Ma, Yidan and Li, Ju and Su, Junchang and Chi, Junxi and Zhu, Xingmiao and Zhu, Xinna and Zhang, Chunzhi and Bi, Changhao and Zhang, Xueli},
title = {Exploring the De Novo NMN Biosynthesis as an Alternative Pathway to Enhance NMN Production},
journal = {ACS Synthetic Biology},
year = {2024},
volume = {13},
number = {8},
pages = {2425--2435},
doi = {10.1021/acssynbio.4c00115}
}
EUVIMED